Inflammatory Biomarker Linked to CHD in Type 2 Diabetes
Lipoprotein-associated phospholipase A2 activity may increase risk of coronary heart disease
THURSDAY, May 27 (HealthDay News) -- The newly recognized inflammatory biomarker lipoprotein-associated phospholipase A2 (Lp-PLA2) appears to be a risk factor for coronary heart disease (CHD) in people with type 2 diabetes, according to research published in the May issue of Diabetes.
Ida J. Hatoum, of the Harvard School of Public Health in Boston, and colleagues measured the Lp-PLA2 activity of 740 men and 777 women with diabetes who were free of cardiovascular disease and cancer at baseline to assess the association of Lp-PLA2 with future coronary events in this population.
In the 10 and 14 years' follow-up of men and women, respectively, the researchers documented 178 and 146 cases, respectively, of CHD, defined as coronary artery bypass graft, angioplasty, nonfatal myocardial infarction, and fatal CHD. After adjusting for other risk factors, the relative risk of total CHD comparing extreme tertiles of Lp-PLA2 was 1.39.
"Levels of Lp-PLA2 activity were significantly associated with incident CHD among men and women with type 2 diabetes, independent of traditional and inflammatory risk factors. This positive association was strongest for more severe clinical end points," the authors write.
Three authors disclosed receiving support from or being employed by GlaxoSmithKline, which partly funded the study.